Food substantially affects oral absorption. This is a product-administration issue, not a suggestion to adjust the dose according to a meal. The short-acting injection has different absorption from a capsule and is not a long-acting depot.
The liver extensively processes ziprasidone through reduction pathways, including aldehyde oxidase, and oxidative pathways involving CYP3A4. Much clearance is not CYP-mediated. The foreign injection contains a cyclodextrin ingredient cleared by the kidneys, so oral and injected formulations must not be assumed to have identical renal precautions.